Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902389 | 0.87 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL4702268 | 0.83 | DPP7 (0.41) | GSRDPP7RRM1GABRR1DPP8 | |
| SCHEMBL20636766 | 0.80 | DPP7 (0.38) | GSRDPP7RRM1GABRR1DPP8 | |
| SCHEMBL29075853 | 0.79 | GSR (0.52) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL997560 | 0.79 | GSR (0.52) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL1537223 | 0.79 | GSR (0.52) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL11531701 | 0.78 | RNPEP (0.37) | — | |
| SCHEMBL20240364 | 0.77 | GSR (0.61) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL16528819 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL344574 | 0.77 | GSR (0.61) | GSRDPP7DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| US-20180243441-A1 | CYTOTOXIC HEXIM1 PEPTIDES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-30 | — | — | US | disclosed |
| EP-3265472-A1 | CYTOTOXIC HEXIM1 PEPTIDES AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-01-10 | — | — | EP | disclosed |
| US-9012567-B2 | Supramolecular polymers and compositions containing said polymers | RHODIA OPERATIONS (FR) | 2015-04-21 | — | — | US | disclosed |
| US-20120289652-A1 | SUPRAMOLECULAR POLYMERS AND COMPOSITIONS CONTAINING SAID POLYMERS | RHODIA OPERATIONS (FR) | 2012-11-15 | — | — | US | disclosed |
| WO-2011047241-A1 | ENHANCED SUBSTRATES FOR THE PROTEASE ACTIVITY OF SEROTYPE A BOTULINUM NEUROTOXIN | DEPARTMENT OF THE US ARMY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243441-A1 | CYTOTOXIC HEXIM1 PEPTIDES AND USES THEREOF | IGF2BP1, L3MBTL1, MYADM | GSR 4541/4885DPP7 822/4885RRM1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.